IFG Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$964K Buy
+1,941
New +$860K 0.03% 435
2026
Q1
Sell
-1,941
Closed -$880K 864
2025
Q4
$880K Hold
1,941
0.04% 393
2025
Q3
$760K Sell
1,941
-44
-2% -$18.4K 0.03% 411
2025
Q2
$884K Buy
1,985
+3
+0.2% +$1.38K 0.04% 378
2025
Q1
$961K Hold
1,982
0.05% 333
2024
Q4
$798K Buy
+1,982
New +$919K 0.05% 332
2024
Q3
Sell
-2,181
Closed -$1.02M 620
2024
Q2
$1.02M Buy
+2,181
New +$947K 0.07% 273
2024
Q1
Sell
-2,319
Closed -$944K 583
2023
Q4
$944K Buy
2,319
+14
+0.6% +$5.17K 0.07% 252
2023
Q3
$802K Buy
+2,305
New +$806K 0.07% 257
2023
Q2
Sell
-2,342
Closed -$738K 503
2023
Q1
$738K Sell
2,342
-20
-0.8% -$6K 0.07% 255
2022
Q4
$682K Buy
2,362
+29
+1% +$8.84K 0.07% 265
2022
Q3
$675K Buy
+2,333
New +$671K 0.06% 274
2019
Q3
Sell
-2,264
Closed -$415K 452
2019
Q2
$415K Buy
2,264
+47
+2% +$8.22K 0.07% 226
2019
Q1
$407K Sell
2,217
-158
-7% -$29.2K 0.08% 221
2018
Q4
$393K Buy
2,375
+2
+0.1% +$347 0.09% 210
2018
Q3
$457K Sell
2,373
-12
-0.5% -$2.14K 0.09% 226
2018
Q2
$405K Buy
2,385
+142
+6% +$22K 0.08% 228
2018
Q1
$365K Sell
2,243
-5
-0.2% -$817 0.08% 233
2017
Q4
$336K Buy
+2,248
New +$333K 0.08% 243

Other funds holding VRTX

IFG Advisory's VRTX Position: Q2 2026 in Review

IFG Advisory opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 1,941 shares worth $964K. The stake represents 0.03% of the portfolio and ranks #435 among its holdings. This is a return to the name: IFG Advisory previously reported a position in VRTX as recently as Q4 2025.

IFG Advisory first reported a position in VRTX in Q4 2017 and has held it in 19 quarters since. The position peaked at $1.02M in Q2 2024. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • IFG Advisory held 1,941 shares of Vertex Pharmaceuticals worth $964K as of Q2 2026.
  • Vertex Pharmaceuticals was a new IFG Advisory position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.03% of IFG Advisory's portfolio in Q2 2026, its #435 holding.
  • IFG Advisory first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 19 quarters since.
  • IFG Advisory's Vertex Pharmaceuticals position peaked at $1.02M in Q2 2024.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on IFG Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.